Healthcare

In its announcement dated 6 October 2026, Neurizon said it had received written responses from the US Food and Drug Administration (FDA) to its Type C meeting request for NUZ-001. The feedback covered the clinical development plan, potential regulatory pathways and the use of …

ALA-101 is an allogeneic CD19-targeting CAR-iNKT cell therapy being tested in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and certain leukaemias. Arovella said its priority is to obtain preliminary clinical safety and efficacy data in blood cancers while advancing its second program, ALA-105, …

The company describes the change as planned, and it follows a 10-year period over which Dr Hinch contributed to the business, according to the Chairman. The Board has not named a permanent successor and says it will advise the market of an appointment in …

Argent describes itself as a revenue-generating specialty biopharmaceutical company, with CimetrA as the lead immune-modulation platform for inflammatory and autoimmune diseases, supported by NanoBodies and peptide technologies, proprietary drug delivery systems and manufacturing capabilities.

Resonance Health Limited (ASX:RHT) is in a trading halt following a request lodged with ASX on 22 October 2026. ASX Supervision published its market announcement on 23 October 2026, confirming that trading in RHT securities would be halted at the company's request, pending the …

BLS Pharmaceuticals Limited is an Australian company that manufactures, develops and commercialises regulated therapeutic products and active pharmaceutical ingredients, operating mainly through its wholly owned subsidiary, Breathe Life Sciences. The company released its first-quarter FY27 report in mid-October 2026, following full-year results in late …

Biome Australia Limited is a microbiome health company that develops, licenses, commercialises and markets evidence-based live biotherapeutics, commonly known as probiotics, and complementary medicines. The company reported record revenue and higher earnings in August 2026, alongside new distribution agreements and a plan to move …